Lamivudin/Zidovudin Puren (Zidovudine, Lamivudine)

Both lamivudine and zidovudine are nucleoside analogues that, after intracellular activation, mimic natural nucleotides. They are incorporated into the viral DNA by HIV reverse transcriptase, causing premature chain termination and preventing the virus from replicating.

The specific dose and dosing schedule are determined by the prescribing clinician based on the patient’s age, weight, renal and hepatic function, and the overall antiretroviral regimen. Patients should follow the prescriber’s instructions precisely.

Safety in pregnancy and breastfeeding has not been fully established. The medication should only be used if the potential benefits to the mother outweigh any possible risks to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lamivudin/Zidovudin combines two nucleoside reverse transcriptase inhibitors, offering a dual mechanism that can simplify regimens compared with using each agent separately. Compared with non‑NRTI classes, it may have a different side‑effect profile and resistance pattern, making it a valuable option in many combination therapies.

Store the tablets at ambient temperature, below 25 °C, in the original container. Keep them away from moisture, direct sunlight and excessive heat to maintain product stability.

The medication is taken orally, usually with or without food, as directed by the prescribing clinician. Swallow the tablet whole with a glass of water and do not crush or split it unless specifically instructed.

Serious risks include severe anemia, lactic acidosis, hypersensitivity reactions, hepatotoxicity, bone‑marrow suppression and pancreatitis. Patients should be monitored regularly for these conditions, and any concerning symptoms should be reported to a healthcare provider immediately.

Individuals with known hypersensitivity to lamivudine, zidovudine, or any excipients in the formulation should avoid this product. It is also contraindicated in patients where monotherapy is planned, as this can promote resistance, and in those with severe pre‑existing anemia or bone‑marrow disorders without close monitoring.